Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
September 22, 2025 10:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).
The analyst comments "This morning PFE announced plans to acquire Metsera (MTSR), a development stage obesity-focused biotech company with a portfolio of candidates (injectable and oral... More
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
September 22, 2025 9:45 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).
The analyst comments "The path forward for Pfizer and Metsera. Topline data from VESPER-1 and interim data from VESPER-3 for MET-097i remain expected by the end of the month. It is our understanding,... More
